Caenorhabditis elegans as a Model System for Duchenne Muscular Dystrophy

被引：5

作者：

Ellwood, Rebecca A. ^{[1
,2
]}

Piasecki, Mathew ^{[1
,2
]}

Szewczyk, Nathaniel J. ^{[1
,2
,3
,4
]}

机构：

[1] Univ Nottingham, Med Res Council MRC Versus Arthrit, Ctr Musculoskeletal Ageing Res, Royal Derby Hosp, Derby DE22 3DT, England

[2] Nottingham Biomed Res Ctr, Natl Inst Hlth Res, Derby DE22 3DT, England

[3] Ohio Univ, Ohio Musculoskeletal & Neurol Inst, Athens, OH 45701 USA

[4] Ohio Univ, Dept Biomed Sci, Heritage Coll Osteopath Med, Athens, OH 45701 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2021年 / 22卷 / 09期

基金：

英国生物技术与生命科学研究理事会;

关键词：

DMD; C; elegans; dystrophin; muscle; CARBONIC-ANHYDRASE-III; MUSCLE DEGENERATION; MDX MOUSE; ALPHA-CATULIN; BK CHANNEL; DYSTROBREVIN; GENE; INHIBITION; EXPRESSION; INTEGRITY;

D O I：

10.3390/ijms22094891

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The nematode worm Caenorhabditis elegans has been used extensively to enhance our understanding of the human neuromuscular disorder Duchenne Muscular Dystrophy (DMD). With new arising clinically relevant models, technologies and treatments, there is a need to reconcile the literature and collate the key findings associated with this model.

引用

页数：19

共 50 条

[21] Exon skipping: a first in class strategy for Duchenne muscular dystrophy
Niks, Erik H.
Aartsma-Rus, Annemieke
EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (02) : 225 - 236
[22] Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy
Jensen, L.
Petersson, S. J.
Illum, N. O.
Laugaard-Jacobsen, H. C.
Thelle, T.
Jorgensen, L. H.
Schroder, H. D.
JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, 2017, 17 (02) : 8 - 18
[23] Immunoproteasome in animal models of Duchenne muscular dystrophy
Chen, Chiao-nan Joyce
Graber, Ted G.
Bratten, Wendy M.
Ferrington, Deborah A.
Thompson, LaDora V.
JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, 2014, 35 (02) : 191 - 201
[24] The Interplay of Mitophagy and Inflammation in Duchenne Muscular Dystrophy
Reid, Andrea L.
Alexander, Matthew S.
LIFE-BASEL, 2021, 11 (07):
[25] The Future of Exon Skipping for Duchenne Muscular Dystrophy
Aartsma-Rus, Annemieke
HUMAN GENE THERAPY, 2023, 34 (9-10) : 372 - 378
[26] Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy
Mucha, Olga
Podkalicka, Paulina
Kazirod, Katarzyna
Samborowska, Emilia
Dulak, Jozef
Loboda, Agnieszka
SKELETAL MUSCLE, 2021, 11 (01)
[27] Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy
Barthelemy, Ines
Pinto-Mariz, Fernanda
Yada, Erica
Desquilbet, Loic
Savino, Wilson
Silva-Barbosa, Suse Dayse
Faussat, Anne-Marie
Mouly, Vincent
Voit, Thomas
Blot, Stephane
Butler-Browne, Gillian
DISEASE MODELS & MECHANISMS, 2014, 7 (11) : 1253 - 1261
[28] Reduced IGF signaling prevents muscle cell death in a Caenorhabditis elegans model of muscular dystrophy
Oh, Kelly Hyunju
Kim, Hongkyun
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (47) : 19024 - 19029
[29] Respiratory characterization of a humanized Duchenne muscular dystrophy mouse model
Roger, Angela L.
Biswas, Debolina D.
Huston, Meredith L.
Le, Davina
Bailey, Aidan M.
Pucci, Logan A.
Shi, Yihan
Robinson-Hamm, Jacqueline
Gersbach, Charles A.
ElMallah, Mai K.
RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2024, 326
[30] Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy
Cai, Aojie
Kong, Xiangdong
HUMAN GENE THERAPY METHODS, 2019, 30 (03) : 71 - 80

← 1 2 3 4 5 →